RA Capital Management’s Scribe Therapeutics SCTX Stock Holding History
Bought
Maintained
Sold
Other funds holding SCTX
BBA
RA Capital Management's SCTX Position: Q3 2026 in Review
RA Capital Management opened a new position in Scribe Therapeutics (SCTX) in Q3 2026: 1,802,178 shares worth $33.2M. The stake represents 0.33% of the portfolio and ranks #44 among its holdings.
62 funds tracked by Wall St. Rank hold SCTX as of Q3 2026.
- RA Capital Management held 1,802,178 shares of Scribe Therapeutics worth $33.2M as of Q3 2026.
- Scribe Therapeutics was a new RA Capital Management position in Q3 2026.
- Scribe Therapeutics made up 0.33% of RA Capital Management's portfolio in Q3 2026, its #44 holding.
- 62 funds tracked by Wall St. Rank held Scribe Therapeutics as of Q3 2026.
Based on RA Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.